PDCD1 and cancer: Over the last couple of decades, PD-1/PD-L1 immune checkpoint inhibitors (ICIs) have been developed and tested in a myriad of cancer types with most exhibiting impressive clinical outcomes such as improved overall survival (OS), durable response and long-term clinical benefit, compared with conventional treatment approaches (6, 13, 16–21).